Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Infliximab (Remicade®) Plus Intravenous Immunoglobulin (IVIG) for the Primary Treatment of Patients With Acute Kawasaki Disease

NCT00760435 is registered in ClinicalTrials.gov with University of California, San Diego as lead sponsor.

NCT NCT00760435
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00760435 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Infliximab (Remicade®) Plus Intravenous Immunoglobulin (IVIG) for the Primary Treatment of Patients With Acute Kawasaki Disease
Lead sponsor
University of California, San Diego
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2009
Completion date
October 31, 2012
Enrollment
196 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

kawasaki disease